Press release
Angina Pectoris - Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments
As per Global Insight services' assessment, about 9 prominent pharma and biotech giants are working on 9 drugs in the Angina Pectoris - pipeline landscape globally. Angina Pectoris Pipeline Insight, 2023" report by Global Insight Services provides a comprehensive analysis of the ongoing clinical development activities and growth prospect.Download PDF Sample Pages to Get an in-depth Assessment of the Emerging Therapies and Key Companies: https://www.globalinsightservices.com/request-sample/GIS31270
Angina also known as angina pectoris, is a type of chest pain or discomfort that occurs when a part of the heart doesn't get enough blood and oxygen, which is due to the spasm or obstruction of the arteries that supply the blood to the heart muscles. Angina is mainly of four types: stable angina, unstable angina, microvascular angina, and vasospastic or variant angina.
Angina is caused due to the built up of plaque in the arteries. The major risk factors that are concerned with angina are smoking, age, stress, lack of physical activity, family history of premature cardiovascular diseases. Medical conditions that exacerbate angina are diabetes, dyslipidaemia, hypertension, kidney disease, polycythaemia, and it is also concerned with the use of medications such as vasodilators.
Symptoms that are associated with angina are chest pain or discomfort. Pain around epigastrium, neck, shoulders and back. Autonomic symptoms include nausea, vomiting, pallor, shortness of breath, squeezing and fatigue.
Angina can be diagnosed with the primary complains including chest pain or discomfort, chest tightness and precipitated by cold weather or a meal. Electrocardiogram is recommended to determine the ST elevations. Non-invasive testing includes coronary angiogram. Imaging testing includes echocardiogram, CT and MRI.
Read more about Angina Pectoris Pipeline Insight here: https://www.globalinsightservices.com/reports/angina-pectoris-drug-pipeline-landscape/
Methodology:
The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.
Scope:
The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.
Major pharmaceutical companies are involved in the development of potential drug candidates to improve the Angina Pectoris treatment such as Ad5FGF-4, AR36, ACP-01 and others. Key players involved in the development of therapies to treat Angina Pectoris are Azurity Pharmaceuticals, Gene Biotherapeutics, Hemostemix Inc, Milestone Pharmaceuticals Inc, XyloCor Therapeutics Inc, and others. Two drugs are under late-stage Phase III clinical trials and four drugs are in Phase II clinical trials and some other drugs are under Phase I, Preclinical and Discovery stages of development.
For In-Depth Competitive Analysis, Purchase this Report: https://www.globalinsightservices.com/checkout/single_user/GIS31270
Report Covers the Emerging Pipeline Products Under Different Phases of Clinical Development Like:
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Contact Us:
Global Insight Services LLC
16192, Coastal Highway, Lewes DE 19958
E-mail: info@globalinsightservices.com
Phone: +1-833-761-1700
About Global Insight Services:
Global Insight Services (GIS) is a leading multi-industry market research firm headquartered in Delaware, US. We are committed to providing our clients with highest quality data, analysis, and tools to meet all their market research needs. With GIS, you can be assured of the quality of the deliverables, robust & transparent research methodology, and superior service.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Angina Pectoris - Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments here
News-ID: 2942878 • Views: …
More Releases from Global Insight Services

Immuno Oncology Drugs Market Projected to Reach $634.1 Billion by 2034, Growing …
The Immuno Oncology Drugs Market is rapidly emerging as a transformative segment in the global healthcare industry. These drugs harness the body's immune system to identify and attack cancer cells, offering innovative treatment alternatives to traditional chemotherapy and radiation therapies. Immuno-oncology therapies include monoclonal antibodies, checkpoint inhibitors, cancer vaccines, and cell-based therapies such as CAR-T cells. The growth of this market is primarily driven by advancements in biotechnology, an improved…

GLP 1 Market Projected to Reach $221.8 Billion by 2034, Growing at 9% CAGR | Ove …
The GLP 1 Market is experiencing unprecedented growth, fueled by the rising prevalence of type 2 diabetes and obesity globally. GLP-1, or glucagon-like peptide-1 receptor agonists, represents a groundbreaking therapeutic class that improves insulin secretion, reduces glucagon production, and slows gastric emptying. These mechanisms not only enhance glycemic control but also support weight management, making GLP-1 therapies a preferred choice among healthcare providers and patients alike. Over the years, the…

Autonomous Bus Market to Expand to $11.6 Billion by 2034, Advancing at 18.8% CAG …
Market Overview
Autonomous Bus Market is revolutionizing the future of urban mobility through advanced automation technologies. Valued at $2.1 billion in 2024, the market is projected to reach $11.6 billion by 2034, expanding at a strong CAGR of 18.8%. This market focuses on the development and deployment of self-driving buses equipped with cutting-edge sensors, artificial intelligence, and vehicle-to-everything (V2X) communication systems. These buses are designed to improve road safety, enhance passenger…

Automotive Tire Market to Attain $976.7 Billion by 2034, Growing at 9.2% CAGR | …
Market Overview
Automotive Tire Market is experiencing remarkable growth as the industry embraces innovation, sustainability, and digital transformation. Valued at $406 billion in 2024, the market is projected to soar to $976.7 billion by 2034, reflecting a CAGR of 9.2%. This expansion is primarily driven by the surge in global vehicle production, growing consumer preference for durable and high-performance tires, and the increasing adoption of smart tire technologies. The Automotive Tire…
More Releases for Angina
Surging Prevalence Of Cardiovascular Diseases Propels Growth In The Angina Pecto …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
How Large Will the Angina Pectoris Drugs Market Size By 2025?
The market size for angina pectoris drugs has experienced consistent growth in the past few years. The market is projected to expand from $12.32 billion in 2024 to $12.88 billion in 2025, representing a compound annual growth rate…
Angina (Angina Pectoris) Pipeline: 10+ Companies Transforming Chest Pain Managem …
The angina therapeutics pipeline is experiencing a renaissance, driven by pharmaceutical companies such as Abbott Laboratories, AstraZeneca, Bayer AG, and Bristol-Myers Squibb. With a focus on improving myocardial efficiency and reducing ischemic burden, emerging therapies-including metabolic modulators, nitric oxide donors, and gene therapies-aim to offer more effective symptom relief and reduce cardiovascular events. Innovations are targeting both stable and microvascular angina forms, addressing the significant unmet needs in chronic angina…
What's Driving the Angina Market 2025-2034: The Rising Prevalence of Coronary Ar …
What Are the Projections for the Size and Growth Rate of the Angina Market?
The scale of the angina market has seen robust growth in the previous years. The expansion is expected to continue, increasing from a value of $10.71 billion in 2024 to $11.4 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 6.4%. The surge in the past period can be credited to factors such as a…
Angina Pectoris - Drug Pipeline Landscape, 2022
Global Angina Pectoris Market report from Global Insight Services is the single authoritative source of intelligence on angina pectoris market. The report will provide you with analysis of impact of latest market disruptions such as Russia-Ukraine war and Covid-19 on the market. Report provides qualitative analysis of the market using various frameworks such as Porters' and PESTLE analysis. Report includes in-depth segmentation and market size data by categories, product types,…
Angina Pectoris - Drug Pipeline Landscape, 2022
Angina also known as angina pectoris, is a type of chest pain or discomfort that occurs when a part of the heart doesn't get enough blood and oxygen, which is due to the spasm or obstruction of the arteries that supply the blood to the heart muscles. Angina is mainly of four types: stable angina, unstable angina, microvascular angina, and vasospastic or variant angina.
Angina is caused due to the built…
Angina Pectoris Drugs Market Set for Rapid Growth
Global Angina Pectoris Drugs Market: Overview
The demand within the global market for angina pectoris drugs has been rising on account of the focus given on treating medical conditions suffered by the geriatric population. The presence of a seamless industry for healthcare diagnostic and treatment has played a major role in market growth. Angina pectoris is a type of chest pain that is triggered due to reduced blood flow to…